Direxion Daily CSI China Internet Bull 2X Shares vs Roivant Sciences Ltd. Common Shares — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.94 (market cap $173.62M), while Roivant Sciences Ltd. Common Shares trades at $35.54 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 142.4× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| CWEB | ROIV | |
|---|---|---|
Market Cap | $173.62M | $24.72B |
Volume | 551,726 | 6,279,442 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $41.81 |
52-Week Low | $17.39 | $16.04 |
Typical Hold Time | 24 Days | 1 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.
The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →